COVID-19
It was a very busy week for clinical trial announcements, although there were only three that were COVID-19-related. Here’s a look.
This marks the second vaccine against the novel coronavirus developed by the India-based company and brings a significant milestone for intranasal formulations.
President Joe Biden took an aggressive step that mandates vaccination for 100 million Americans who are eligible for preventative medication.
A recently published study points to a previous SARS infection—plus vaccination—as the key to a robust immunity against SARS-CoV-2.
This week, the mRNA leader followed up its announcement of a collaboration with the Institute for Life Changing Medicines (ILCM), with an update on several programs advancing in its pipeline.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The FDA stated that it could not determine if the use of lenzilumab in COVID patients outweighs the known and potential safety risks.
Heading into fall, with the COVID-19 pandemic surging again and researchers tracking new variants, there’s plenty of news. Here’s a look.
The Biden administration announced plans for a new biopreparedness initiative that is part of the ongoing Building Back Better plan.
Concerns about Mu and Lambda are growing, but data suggests that Delta is still the biggest problem. The U.S. is also struggling with infections this year. Here’s the latest news.
PRESS RELEASES